TW200640463A - Use of sodium channel blockers and their analogues for the treatment of nicotine dependency - Google Patents

Use of sodium channel blockers and their analogues for the treatment of nicotine dependency

Info

Publication number
TW200640463A
TW200640463A TW095104602A TW95104602A TW200640463A TW 200640463 A TW200640463 A TW 200640463A TW 095104602 A TW095104602 A TW 095104602A TW 95104602 A TW95104602 A TW 95104602A TW 200640463 A TW200640463 A TW 200640463A
Authority
TW
Taiwan
Prior art keywords
analogues
treatment
sodium channel
channel blockers
nicotine dependency
Prior art date
Application number
TW095104602A
Other languages
Chinese (zh)
Inventor
Helmut Henrich Buschmann
Gomis Farre
Hernandez Jose Miguel Vela
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05384001A external-priority patent/EP1690541A1/en
Priority claimed from EP05384002A external-priority patent/EP1714655A1/en
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of TW200640463A publication Critical patent/TW200640463A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention refers to the use of a sodium channel blocker such as tetrodotoxin or saxitoxin, their analogues and derivatives, their physiologically acceptable salts, as well as their possible combination with nicotine in medicinal products for human and/or animal therapeutics for the treatment of nicotine dependency.
TW095104602A 2005-02-11 2006-02-10 Use of sodium channel blockers and their analogues for the treatment of nicotine dependency TW200640463A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05384001A EP1690541A1 (en) 2005-02-11 2005-02-11 Use of a sodium channel blocker and their analogues for the treatment of nicotine dependency
EP05384002A EP1714655A1 (en) 2005-04-22 2005-04-22 Use of sodium channel blockers and their analogues for the treatment of nicotine dependency

Publications (1)

Publication Number Publication Date
TW200640463A true TW200640463A (en) 2006-12-01

Family

ID=36636342

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095104602A TW200640463A (en) 2005-02-11 2006-02-10 Use of sodium channel blockers and their analogues for the treatment of nicotine dependency

Country Status (6)

Country Link
EP (1) EP1853268A1 (en)
AR (1) AR053811A1 (en)
CA (1) CA2597101A1 (en)
PE (1) PE20061036A1 (en)
TW (1) TW200640463A (en)
WO (1) WO2006084765A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201602576D0 (en) 2016-02-12 2016-03-30 Bergen Teknologioverforing As Process

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1888195A (en) * 1994-03-17 1995-10-03 Nanning Maple Leaf Pharmaceutical Co. Ltd. The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence
CN1284536C (en) * 2000-09-18 2006-11-15 威克斯医药有限公司 Antalgic method by general medicine application

Also Published As

Publication number Publication date
EP1853268A1 (en) 2007-11-14
WO2006084765A1 (en) 2006-08-17
AR053811A1 (en) 2007-05-23
PE20061036A1 (en) 2006-11-24
CA2597101A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
TNSN08326A1 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
MX2020008616A (en) Sublingual fentanyl spray.
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
TW200801022A (en) Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
WO2007128817A3 (en) Insulin derivative
NO20081592L (en) Dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
MY145447A (en) Use of 2-6(3-amino-piperidin-1-yl)-3-methyl-2, 4-dioxo-3, 4-dihydrp-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
MX2009002196A (en) Buprenophine-wafer for drug substitution therapy.
MY149854A (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
MX2009004561A (en) Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain.
WO2007025212A3 (en) Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
IL208751A0 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
EP2801358A3 (en) The use of nicotine for diminishing pain in renal region in humans
MX341660B (en) Ghrelin receptor agonist for treatment of dyscrasia.
TW200640463A (en) Use of sodium channel blockers and their analogues for the treatment of nicotine dependency
EA200801678A1 (en) APPLICATION OF TRIAZINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICINE PRODUCT WITH A HEALING OR ANGIOGEN EFFECT
HK1111924A1 (en) Depigmenting or brightening cosmetic composition comprising at least one oxazolin as an active ingredient
MX2008013477A (en) Bicyclic tetrahydropyrrole compounds.
TW200700084A (en) Combination of sodium channel blockers and their derivatives with opioid antagonists
WO2006087147A3 (en) Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia